Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging

British Journal of Cancer

Volumn 88, Issue 10, 2003, Pages 1592-1597

  Robinson, S P ^a,c   McIntyre, D J O ^a   Checkley, D ^b   Tessier, J J ^b   Howe, F A ^a   Griffiths, J R ^a   Ashton, S E ^b   Ryan, A J ^b   Blakey, D C ^b   Waterton, J C ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

MRI; Response biomarker; Tumour perfusion; Vascular targeting agents; ZD6126

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYHEMOGLOBIN; GADODIAMIDE; N ACETYLCOLCHINOL PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; FIBROSARCOMA; HISTOPATHOLOGY; IMAGE ANALYSIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTINOMA; QUANTITATIVE ANALYSIS; RAT; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TECHNIQUE; TREATMENT INDICATION; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSARCOMA; MAGNETIC RESONANCE IMAGING; MICE; NECROSIS; ORGANOPHOSPHORUS COMPOUNDS; PITUITARY NEOPLASMS; PROLACTINOMA; RATS; REGIONAL BLOOD FLOW; TUMOR MARKERS, BIOLOGICAL;

EID: 0037778194     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600926     Document Type: Article

References (29)

1. Abramovitch R, Dafni H, Smouha E, Benjamin LE, Neeman M (1999) In vivo prediction of vascular susceptibility to vascular endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 59: 5012-5016
2. Beauregard DA, Pedley RB, Hill SA, Brindle KM (2002) Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15: 99-105
3. Blakey DC, Douglas S, Revill M, Ashton SA (1999) The novel vascular targeting agent ZD6126 causes rapid morphology changes leading to endothelial cell detachment at non-cytotoxic concentrations. Clin Exp Metastasis 17: 776
4. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Anti-tumour activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8: 1974-1983
5. Chaplin DJ, Dougherty GJ (1999) Tumour vasculature as a target for cancer therapy. Br J Cancer 80 (Suppl 1): 57-64
6. Checkley D, Curry B, Dukes M, Kendrew J, Tessier JJ, Waterton JC, Wedge SR (1999) Effect of ZD4190, a VEGF receptor tyrosine kinase inhibitor, on endothelial permeability in human tumour xenografts. Proc Int Soc Magn Reson Med 2: 1324
7. Checkley D, Tessier JJ, Wedge SR, Dukes M, Kendrew J, Waterton JC (2001) ZD6474, a VEGF signalling inhibitor: effects on DCEMRI in human tumour xenografts and approaches to the analysis of the Ktrans maps. Proc Int Soc Magn Reson Med 1: 478
8. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 57: 1829-1834
9. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MRL, Chaplin DJ, Hill SA (2002) ZD6126; a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62: 7247-7253
10. Denekamp J (1993) Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66: 181-196
11. Denekamp J, Hobson B (1982) Endothelial-cell proliferation in experimental tumours. Br J Cancer 46: 711-720
12. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase 1 pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408-3416
13. Evelhoch JL (1999) Key factors in the acquisition of contrast kinetic data in oncology. J Magn Reson Imag 10: 254-259
14. Evelhoch JL, LoRusso P, DelProposto Z, Stark K, Latif Z, Morton P, Waterton JC, Wheeler C, Barge A (2002) Dynamic contrast-enhanced MRI evaluation of the effects of ZD6126 on tumor vasculature in a phase I clinical trial. Proc Intl Soc Magn Reson Med, 2095
15. Galbraith SM, Rustin GJS, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20: 3826-3840
16. Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S (2002) Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinomas in nude mice. Cancer Res 62: 3711-3715
17. Howe FA, Robinson SP, Rodrigues LM, Griffiths JR (1999) Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumours to carbogen breathing. Magn Reson Imaging 17: 1307-1318
18. Howe FA, Robinson SP, McIntyre DJO, Stubbs M, Griffiths JR (2001) Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 14: 497-506
19. Kostourou V, Robinson SP, Cartwright JE, Whitley GSTJ (2002) Dimethylarginine dimethylaminohydrolase 1 enhances tumour growth and angiogenesis. Br J Cancer 87: 673-680
20. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman M, Jackson A, Jayson G, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani A, Price P, Rathbone R, Rustin G, Tofts P, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P (2003) Assessment of anti-angiogenic and anti-vascular therapeutics using magnetic resonance imaging: recommendations for appropriate methodology for clinical trials. Proc Int Soc Magn Reson Med 1: 1268
21. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, Tozer GM (2002) Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15: 89-98
22. Menke H, Vaupel P (1988) Effect of injectable or inhalational anaesthetics and of neuroleptic, neuroleptanalgesic, and sedative agents on tumor blood flow. Radiat Res 114: 64-76
23. Prysor-Jones RA, Jenkins JS (1981) Effect of bromocriptine on DNA synthesis, growth and hormone secretion of spontaneous pituitary tumours in rat. J Endocrinol 88: 463-469
24. 2* and arterial blood gases. Magn Reson Imaging 19: 161-166
25. Siemann DW, Rojiani AM (2001) Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53: 164-171
26. Thulborn KR, Waterton JC, Matthews PM, Radda GK (1982) Oxygenation dependence of the transverse relaxation time of water protons in whole blood at high field. Biochim Biophys Acta 714: 265-270
27. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ (2001) Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61: 6413-6422
28. Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA, Kallman RF (1980) A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst 64: 595-604
29. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom co-ordinating committee on cancer research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1-10